Zydus's Saroglitazar shows positive results in Patients with Primary Biliary Cholangitis
Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences Ltd., a global innovation led healthcare company, announced positive topline results from the pivotal EPICS-III Phase 2(b)/3 clinical trial.




















